John Carroll, founder and editor of Endpoints News, with Sebastian Guth, Bayer Pharmaceuticals' president for the Americas, at an Endpoints News event in San Diego on June 14, 2022

Con­nect with End­points News — here's our ma­jor event cal­en­dar com­ing up in H2 2022

The room was packed and elec­tric. That’s how it felt host­ing an event in per­son for End­points News read­ers last month in San Diego.

It ex­ceed­ed all our ex­pec­ta­tions, which wasn’t a giv­en, with the pan­dem­ic chang­ing the na­ture of live events. We hadn’t done one in over two years. And End­points grew a lot dur­ing that time. We quick­ly built a se­ri­ous vir­tu­al events plat­form and de­vel­oped big au­di­ences around those on­line chan­nels. But there’s noth­ing quite like be­ing with your col­leagues at a live event. End­points has a tra­di­tion of con­ven­ing our au­di­ence of bio­phar­ma pros in ma­jor hubs world­wide since our start in 2016. And we’re thrilled to jump right back in.

With a wrap on BIO, AS­CO, Cannes and oth­er crit­i­cal in­dus­try mee­tups, there are sev­er­al key dates ahead on the End­points cal­en­dar to at­tend — both live and in-per­son. And spon­sor­ship op­por­tu­ni­ties re­main for bio­phar­ma mar­keters. Here’s what’s on deck:

Ma­jor End­points events

The End­points 11 (Sep­tem­ber 22, Boston) — Big dreams dom­i­nate among next-gen biotech play­ers. Our an­nu­al E11 se­ries is back to hon­or the up­starts most poised for im­pact — an event that al­so marks John Car­roll’s 20th year spot­light­ing pri­vate biotechs. Join us vir­tu­al­ly or in per­son at an ex­clu­sive event in Boston. Past events: 2021, 2020 | Cov­er­age: 2021, 2020

#EU­BIO22 (Oc­to­ber 12, Lon­don) — The bio­phar­ma view from the con­ti­nent. Read­ers can sign up to stream the full line­up — or pur­chase a tick­et to join us in Lon­don that af­ter­noon — as John Car­roll and Sil­i­con Val­ley Bank’s Nooman Haque host a se­ries of pan­els and fire­side chats as­sess­ing the lat­est M&A, R&D and reg­u­la­to­ry trends fac­ing Eu­rope’s bio­phar­ma in­dus­try.

Women in Bio­phar­ma (De­cem­ber 7, vir­tu­al) — Tak­ing the lead in R&D. You won’t want to miss one of our most pop­u­lar an­nu­al re­ports pro­fil­ing 20 of the in­dus­try’s most in­flu­en­tial women ex­ec­u­tives. Our ed­i­tors will host a spe­cial pre­sen­ta­tion high­light­ing this year’s hon­orees and sub­se­quent pan­el dis­cus­sion prob­ing what’s ahead for di­ver­si­ty and in­clu­sion ini­tia­tives.

Con­fer­ence cov­er­age and events

#ES­MO22 (Sep­tem­ber 12, vir­tu­al) — What’s new in on­col­o­gy in R&D? Our jour­nal­ists will re­port live from Paris with break­ing news and read­outs from the show and re­lease a spe­cial ES­MO re­port on Sep­tem­ber 12. You can al­so tune in live for EIC John Car­roll’s vir­tu­al fire­side with a lead­ing news­mak­er at ES­MO and his sub­se­quent pan­el analy­sis of the con­fer­ence’s biggest wins and loss­es.

#ASH22 (De­cem­ber 12, vir­tu­al) — Cell and gene ther­a­pies are head­ed to crit­i­cal mile­stones. Our glob­al au­di­ence can livestream John Car­roll’s fire­side chat and pan­el re­view un­pack­ing the in­dus­try’s most close­ly watched cell and gene ther­a­pies. If you miss the livestream, you’ll find this year’s spe­cial ASH re­port in your in­box on De­cem­ber 12.

#CPHI (Oc­to­ber 27, spe­cial re­port) — End­points Man­u­fac­tur­ing will have a spe­cial edi­tion cov­er­ing the lat­est in­no­va­tions in phar­ma man­u­fac­tur­ing and de­vel­op­ment in ad­vance of the big CPHI event in Frank­furt.

And, as al­ways, our sum­mer sights are set square­ly in San Fran­cis­co this Jan­u­ary for JP Mor­gan. More to come as we pre­pare for wall-to-wall cov­er­age at the in­dus­try’s pre­mier kick­off event.

For all event ad­ver­tis­ing, sched­ul­ing and pric­ing re­quests, con­tact our sales team di­rec­tors Melis­sa Naz­zaro (melis­sa@end­ and Julie No­tario (jno­tario@end­


For our full me­dia kit, vis­it End­points Stu­dio — our in-house mar­ket­ing agency led by Kari Abit­bol that con­nects bio­phar­ma mar­keters with their tar­get au­di­ences di­rect­ly on the End­points plat­form.

If you want to reach out to the ed­i­to­r­i­al team with sug­ges­tions, email ed­i­tor@end­

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

FDA ad­vi­sors unan­i­mous­ly rec­om­mend ac­cel­er­at­ed ap­proval for Bio­gen's ALS drug

A panel of outside advisors to the FDA unanimously recommended that the agency grant accelerated approval to Biogen’s ALS drug tofersen despite the drug failing the primary goal of its Phase III study, an endorsement that could pave a path forward for the treatment.

By a 9-0 vote, members of the Peripheral and Central Nervous System Drugs Advisory Committee said there was sufficient evidence that tofersen’s effect on a certain protein associated with ALS is reasonably likely to predict a benefit for patients. But panelists stopped short of advocating for a full approval, voting 3-5 against (with one abstention) and largely citing the failed pivotal study.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Alaa Halawa, executive director at Mubadala’s US venture group

The ven­ture crew at Mubadala are up­ping their biotech cre­ation game, tak­ing care­ful aim at a new fron­tier in drug de­vel­op­ment

It started with a cup of coffee and a slow burning desire to go early and long in the biotech creation business.

Wrapping up a 15-year discovery stint at Genentech back in the summer of 2021, Rami Hannoush was treated to a caffeine-fueled review of the latest work UCSF’s Jim Wells had been doing on protein degradation — one of the hottest fields in drug development.

“Jim and I have known each other for the past 15 years through Genentech collaborations. We met over coffee, and he was telling me about this concept of the company that he was thinking of,” says Hannoush. “And I got immediately intrigued by it because I knew that this could open up a big space in terms of adding a new modality in drug discovery that is desperately needed in pharma.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Sanofi, Re­gen­eron boast PhI­II win with Dupix­ent in COPD, clear­ing first bar for ex­pan­sion

Dupixent, the blockbuster anti-inflammatory drug from Sanofi and Regeneron, has cleared a high-stakes Phase III study in chronic obstructive pulmonary disease, the companies announced Thursday morning.

If they hold up in a second, identical trial, the data pave the way for Dupixent to become the first biologic to treat patients whose COPD remains uncontrolled despite being on maximal standard-of-care inhaled therapy — the patient population studied in the pivotal program. The companies had spotlighted this as a key readout as they look to expand the Dupixent franchise and explore its full potential.

Genen­tech to stop com­mer­cial man­u­fac­tur­ing at Cal­i­for­nia head­quar­ters

Genentech is halting commercial manufacturing at its California headquarters — and laying off several hundred employees.

The move is the result of a decision Genentech made in 2007 to relocate manufacturing operations from its South San Francisco headquarters location to other facilities or move the work to CDMOs, said Andi Goddard, Genentech’s SVP of quality and compliance for pharmaceutical technical operations, in an interview with Endpoints News. Genentech has made changes in capabilities and invested more in technology, so it doesn’t need as many large-scale manufacturing facilities as it did in the past, she said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Chat­G­PT with phar­ma da­ta de­buts for med­ical meet­ings, be­gin­ning with AACR

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

In­cyte wins ac­cel­er­at­ed ap­proval for PD-1 in rare skin can­cer

Incyte touted an accelerated approval for its PD-1 retifanlimab in a rare skin cancer on Wednesday, roughly a year and a half after the drug suffered a rejection in squamous cell carcinoma of the anal canal (SCAC).

Retifanlimab, marketed as Zynyz, was approved for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a fast-growing skin cancer typically characterized by a single, painless nodule. It’s roughly 40 times rarer than melanoma, according to the nonprofit Skin Cancer Foundation — but incidence is growing, particularly among older adults, Incyte said in its announcement.

A new study finds that many patient influencers are sharing prescription drug experiences along with health information.

So­cial me­dia pa­tient in­flu­encers ‘danc­ing in the gray’ of phar­ma mar­ket­ing, more clar­i­ty need­ed, re­searcher says

It’s no surprise that patient influencers are talking about their health conditions on social media. However, what’s less clear is what role pharma companies are playing, how big the patient influencer industry is, and just how is information about prescription drugs from influencers relayed — and received — on social media.

While University of Colorado associate professor Erin Willis can’t answer all those questions, she’s been researching the issue for several years and recently published new research digging into the communication styles, strategies and thinking of patient influencers, many of whom partner with pharma companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Gian Ehrenzeller/Keystone via AP)

No­var­tis pulls the plug on UK-based car­dio­vas­cu­lar study

Novartis is calling off a UK-based trial for Leqvio in the primary prevention of cardiovascular events in patients with high cholesterol, the company confirmed on Wednesday.

The Swiss pharma giant made the decision after “careful evaluation,” a spokesperson told Endpoints News via email. The trial, dubbed ORION-17, was planned in partnership with England’s National Health Service (NHS) and was part of the company’s strategy to establish Leqvio as a standard of care in cardiovascular disease management.